Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Completed · Phase 2
Conditions studied: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
In brief
The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.
Key facts
- Study ID
- NCT00760084
- Run by
- Eisai Inc.
- People needed
- 10
- Starts
- 2005-07-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2011-08-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Must sign an Institutional Review Board (IRB) -approved informed consent form, indicating his/her awareness of the investigational nature of decitabine and its potential hazards prior to initiation of any study-specific procedures or treatment.
- Must have had one of the following:
- MDS (de novo or secondary) fitting any of the recognized French-American-British classifications
- OR
- chronic myelomonocytic leukemia (with WBC <12,000/μL)
- AND
- an International Prognostic Scoring System score of ≥1.5 as determined by complete blood count, bone marrow assessment and bone marrow cytogenetics within 30 days of study entry OR AML (≥ 30 % bone marrow blasts), except M3 or acute promyelocytic leukemia.
- Must be age 18 years or older.
- Must have completed participation per protocol in the MGI PHARMA DACO-018 decitabine trial.
- Must enroll in this trial no more than 8 weeks after discontinuation from the MGI PHARMA DACO-018 trial.
- Must have recovered from all toxic effects of all prior therapy.
You may not qualify if…
- Must not have any other active malignancy, other than basal or squamous cell skin carcinoma.
- Must not have received in the period after discontinuation from DACO-018 and enrollment into this trial any other chemotherapy agent, including investigational agents, for their disease.
- Must not have evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial, at the discretion of the principal investigator.
- Must not be pregnant or lactating.
Where it is running
- Washington University School of Medicine — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.